Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer - Takeaways - MDSpire

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

  • By

  • Bingbing Li

  • Yuning Ren

  • Xiaoling Zhang

  • April 20, 2026

  • 0 min

Share

  • 1

    Lung cancer is a leading cause of cancer-related mortality, with most patients diagnosed at advanced stages.

  • 2

    Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 pathways have transformed lung cancer treatment.

  • 3

    Challenges in ICI therapy include primary resistance, biomarker limitations, and immune-related adverse events.

  • 4

    ICIs are standard treatment for advanced NSCLC and first-line for extensive-stage SCLC, but long-term benefits are limited.

  • 5

    Personalized immunotherapy is essential due to therapeutic heterogeneity and varying patient responses in lung cancer.

Original Source(s)

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

  • by Bingbing Li, Yuning Ren, Xiaoling Zhang

  • April 20, 2026

Related Content

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy